Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.68 |
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | PNP | P00491 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 5/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.58 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24865920 | 1.00 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2825092 | 1.00 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL15397114 | 1.00 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL17356523 | 1.00 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL28615986 | 0.93 | HINT1 (0.64) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL28981039 | 0.91 | HINT1 (0.57) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3970953 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3514472 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL17355882 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| Guanosine SCHEMBL28005790 | 0.87 | HPGD (0.66) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023159930-A1 | COMPOUND FOR RNA CAPPING AND APPLICATION OF COMPOUND | 广州市恒诺康医药科技有限公司 | 2023-08-31 | — | — | WO | disclosed |
| US-20110182973-A1 | POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS | FREIE UNIVERSITAET BERLIN (DE) | 2011-07-28 | — | — | US | disclosed |
| US-7611718-B1 | chimeric dna viruses; disrupted open reading frame; for treating or preventing viral infections; immunogens | MEDIMMUNE, LLC (US) | 2009-11-03 | — | — | US | disclosed |
| US-7550149-B2 | Attenuation of cytomegalovirus virulence | MEDIMMUNE, LLC (US) | 2009-06-23 | — | — | US | disclosed |
| US-7537770-B2 | chimeric dna viruses comprising nucleotide sequences whose open reading frame is disrupted in the genome region or its homolog, used for treating or preventing viral infections | MEDIMMUNE, LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080019945-A1 | Attenuation of Cytomegalovirus Virulence | MEDLMMUNE VACCINES, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20070292455-A1 | ATTENUATION OF CYTOMEGALOVIRUS VIRULENCE | MEDIMMUNE VACCINES, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-7204990-B1 | Attenuation of cytomegalovirus virulence | MEDIMMUNE VACCINES, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-06-16 | — | — | US | disclosed |
| EP-0683675-A4 | HUMAN MONOCLONAL ANTIBODIES TO CYTOMEGALOVIRUS. | SANDOZ PHARMACEUTICALS CORP (US) | 1997-05-21 | — | — | EP | disclosed |
| EP-0683675-A1 | HUMAN MONOCLONAL ANTIBODIES TO CYTOMEGALOVIRUS | SANDOZ PHARMACEUTICAL CORPORATION (US) | 1995-11-29 | — | — | EP | disclosed |
| WO-1994016730-A1 | HUMAN MONOCLONAL ANTIBODIES TO CYTOMEGALOVIRUS | SANDOZ PHARMACEUTICAL CORPORATION (US) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | HINT1 3008/4885NT5E 1630/4885GSK3A 486/4885 |
| US-20110182973-A1 | POLYMERASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF TUMORS | POLH, POLI, POLK | HINT1 3151/4885NT5E 2917/4885GSK3A 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.